Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.
نویسندگان
چکیده
Secondary non-response (SNR) to botulinum toxin (BoNT) in cervical dystonia (CD) lacks a universal definition. We conducted a retrospective survey to develop a definition based on clinicians' practice. Fifty-seven neurologists completed a 17-item questionnaire. In defining SNR, insufficiently improved posture was considered to be more relevant (98% of physicians) than insufficiently improved pain (86%). The most frequently used diagnostic test for SNR was the frontalis test (68%); antibody testing was performed by only 13% of physicians. Three consecutive unsuccessful injection cycles were considered the most appropriate indicator of SNR (55% of physicians). Physicians reported that 5.9% (median) of patients treated in 2008 became secondary non-responders to BoNT-A. The most common strategy for SNR was optimization of physiotherapy, considered by 98% of the physicians. On the basis of our findings, SNR can be defined as insufficiently improved posture after ≥3 unsuccessful injection cycles in CD patients previously achieving satisfactory results.
منابع مشابه
Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study
OBJECTIVES Real-life data on response to Botulinum toxin A (BoNT-A) in cervical dystonia (CD) are sparse. An expert group of neurologists was convened with the overall aim of developing a definition of treatment response, which could be applied in a non-interventional study of BoNT-A-treated subjects with CD. DESIGN International, multicentre, prospective, observational study of a single inje...
متن کاملBritish Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin
Botulinum toxin (BoNT) injections are an effective treatment for cervical dystonia. Approximately 20% of patients eventually stop BoNT treatment, mostly because of treatment failure. These recommendations review the different therapeutic interventions for optimising the treatment in secondary poor responder patients. Immunoresistance has become less common over the years, but the diagnosis has ...
متن کاملDepletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.
The objective was to evaluate whether removal of neutralising antibodies potentially resensitises a secondary non-responder to botulinum neurotoxin A (BoNT/A). Neutralising antibodies directed against BoNT/A are produced during long term treatment with BoNT/A-hemagglutinin complex in up to 10% of patients with cervical dystonia. These patients become secondary non-responders. Other serotypes of...
متن کاملTreatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis.
We report the case of a 49-year-old woman who has the rare combination of myasthenia gravis and cervical dystonia. She was treated with botulinum toxin type A with good response and no evidence of deterioration of the myasthenic symptoms. We therefore conclude that it is possible to use botulinum toxin in the presence of defective neuromuscular transmission.
متن کاملManagement Challenges in Oromandibular Dystonia: The Role of Botulinum Toxin-A
Background: Oromandibular dystonia is a focal or segmental cranio-cervical dystonia, with diverse incapacitating clinical manifestations. Though botulinum toxin injection has emerged as an effective symptomatic treatment; yet, many unanswered questions are not addressed by the current available studies. Objective: To evaluate the efficacy of Botulinum toxin type A (BTX-A) treatment in patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Functional neurology
دوره 27 4 شماره
صفحات -
تاریخ انتشار 2012